Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Basic Materials
  3. OTC
  4. NVZMY

Market Cap: $30.77B

NA

Novozymes A/S

NVZMY
OTC (Other OTC)USD
Invest in NVZMY
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

Novozymes A/S Financials

Profitability, balance-sheet strength and valuation from the latest reported results (trailing twelve months).

Financial Health Scores

Piotroski F-Score

5/9 · Average

Nine pass/fail checks on profitability, leverage, liquidity and efficiency. 7–9 is strong, 0–3 is weak.

Altman Z-Score

24.36
Distress <1.8Grey 1.8–3Safe >3

Safe zone: low near-term bankruptcy risk.

From Revenue to Profit

How much of each dollar of sales is kept at each stage (last 12 months).

  • Revenue$4.39B100.0%
  • Gross Profit$2.47B56.3%
  • EBITDA$1.24B28.1%
  • Operating Profit (EBIT)$927.02M21.1%
  • Net Profit$684.29M15.6%

Balance Sheet Snapshot

Total assets of $16.83B, funded by:

Liabilities
$5.61B(33%)
Shareholders' equity
$11.22B
Debt / Equity
0.28x
Current Ratio
1.53x

Short-term assets comfortably cover short-term liabilities.

Returns on Capital

How well management turns capital into profit. Above 10–15% is generally considered strong.

  • Return on Equity6.2%

    Profit generated per dollar of shareholders' money.

  • Return on Assets4.0%

    Profit generated per dollar of assets owned.

  • Return on Invested Capital4.9%

    Profit generated on debt and equity invested in the business.

  • Return on Capital Employed6.5%

    Operating profit per dollar of long-term capital.

Valuation at a Glance

Lower multiples can mean cheaper shares, or a market expecting weaker results.

Price / Earnings
40.92x

What investors pay for each dollar of yearly profit.

Price / Book
2.57x

Share price vs net assets per share. Under 1x = below book value.

Price / Sales
5.79x

Market cap vs yearly revenue.

EV / EBITDA
22.43x

Whole-business value (incl. debt) vs operating cash earnings.

Price / Free Cash Flow
36.57x

Market cap vs cash left after capital spending.

PEG Ratio
1.51x

P/E adjusted for earnings growth. Around 1x is often seen as fair.

All Key Metrics

Every trailing-twelve-month ratio behind the charts above, grouped by topic. Pick a category to browse.

Profitability

How much of each dollar of revenue turns into profit at each stage, over the last 12 months.

Gross Profit Margin
56.31%
EBITDA Margin
28.15%
EBIT Margin
21.12%
Pre-tax Margin
19.98%
Net Profit Margin
15.59%
Earnings Yield
2.40%

Valuation Multiples

How the share price compares with earnings, sales, book value and cash flow. Lower multiples can mean cheaper shares, or weaker prospects.

Price / Book
2.57
Price / Sales
5.79
Price / Earnings
40.92
PEG
1.51
Forward PEG
7.07
EV / Sales
6.31
EV / EBITDA
22.43
EV / Operating Cash Flow
22.50
EV / Free Cash Flow
39.84
Price / Free Cash Flow
36.57
Price / Operating Cash Flow
23.52

Cash Flow & Capital

How much cash the business generates, how much it reinvests, and what it returns to shareholders.

Free Cash Flow / Share
$1.47
Operating Cash Flow / Share
$2.61
Free Cash Flow Yield
2.78%
Capex / Revenue
12.21%
Capex / Operating Cash Flow
43.52%
Capex / Depreciation
1.74
Stock Compensation / Revenue
0.00%
Dividend Payout Ratio
60.54%
Dividend Yield
1.44%

Liquidity & Leverage

Whether the company can cover its short-term bills and how heavily it relies on debt.

Current Ratio
1.53
Quick Ratio
0.96
Cash Ratio
0.31
Debt / Assets
0.19
Debt / Capital
0.22
Debt / Equity
0.28
Long-Term Debt / Capital
0.19
Debt / Market Cap
12.36%
Net Debt / EBITDA
2.18
Solvency Ratio
0.18
Financial Leverage
1.50

Efficiency & Working Capital

How quickly the company turns assets, inventory and receivables into sales and cash.

Asset Turnover
0.26
Fixed Asset Turnover
1.36
Inventory Turnover
2.26
Receivables Turnover
4.57
Payables Turnover
5.15
Days Sales Outstanding
79.96
Days Inventory Outstanding
161.56
Days Payables Outstanding
70.85
Operating Cycle
241.52
Cash Conversion Cycle
170.67
Working Capital Turnover
5.24

Returns & Quality

How efficiently management turns shareholders' money and company assets into profit.

Return on Equity
6.17%
Return on Assets
4.05%
Return on Invested Capital
4.93%
ROCE
6.50%
Return on Tangible Assets
11.79%
Operating Return on Assets
5.96%
Income Quality
1.80
Tax Burden
0.78
Interest Burden
0.95

Balance Sheet & Intrinsic Metrics

What the company owns and owes, and asset-based value estimates per share.

Enterprise Value
$27.59B
Invested Capital
$15.05B
Working Capital
$785.7M
Tangible Asset Value
$167.2M
Net Current Asset Value
$-3.34B
Graham Number
$27.91
Graham Net-Net
-$8.52
Book Value / Share
$23.88
Tangible Book Value / Share
$0.36
Cash / Share
$0.99

Financial Health Scores

Composite scores and the latest reported totals behind them.

Piotroski Score
5
Altman Z-Score
24.36
Revenue
$4.39B
EBIT
$996.8M
Market Cap
$214.17B
Working Capital
$785.7M
Retained Earnings
$11.32B
Total Assets
$16.83B
Total Liabilities
$5.61B